Lonza

Articles

Speed to market is a critical aspect of developing new pharmaceutical products, and scale-up-or scale-down-can play a key part in that process. Significant interest has been focused on the science of scale for spray drying, since this process is the leading technology for formulating drugs with slow dissolution rates or poor solubility, which results in low bioavailability. Lonza has over 20 years of experience in the scale-up and scale-down of spray drying processes. To learn more, read our executive summary.

Science of Scale for Spray-Dried Intermediates (July 2024)

The increasing number of breakthroughs in small molecule drug development are exciting, but corresponding workflows are complex and require much more tailored approaches to ensure successful upstream and downstream processing, drug approvals and commercialization.

Accelerating Small Molecule Advancements: The Power of Collaboration Between CDMOs and Biotechs (July 2024)

Navigating Commercial Drug Development Technologies for Formulation Excellence (July 2024)

This webinar focuses on dose-flexible manufacturing strategies and their role in drug development.

https://www.pharmtech.com/pt_w/flexible-dose-development


This webinar focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.

Learn about appropriateness for multiple doses or dose flexibility to enable optimal clinical strategies.

Find out how to select the best various drug delivery and manufacturing technologies to achieve the required dose flexibility.

Discover how risk assessment strategies can be put in place when determining the best technology option for a dose-flexible approach.

Pediatric, Oncology and patient-focused innovators


Head of Multiparticulate Product Development
Lonza

Jonathan Cape, is Head of Multiparticulate Product Development at Lonza, where he has worked for 13 years in roles ranging from R&D to chemist, to technology manager. Jon earned his PhD in Biochemistry from Washington State University and has held postdoctoral positions at Washington State University and Los Alamos National Laboratory. Jon currently manages Lonza's Multiparticulate Product Development team and is focused on developing impactful patient-centric drug products.




Product Development Engineer III
Lonza

Kaylee Eyerly is a Product Development Engineer at Lonza. She has six years of experience in the pharmaceutical industry. She holds a Honors BSc in Chemical Engineering from Oregon State University. She has experience in formulation, process development, and manufacturing in every clinical stage, with specific expertise in late-stage programs, primarily specializing in multiparticulates and spray layered dispersions.


